Table 2.

GCV, FOS, and CDV susceptibility phenotypes of pol mutants

BAC	Virus	UL54 pol genotype		Ganciclovir				Foscarnet				Cidofovir
		Mutationa	Otherb	EC50c	SDd	Ne	EC50 ratiof (fold change)	EC50	SD	N	EC50 ratio (fold change)	EC50	SD	N	EC50 ratio (fold change)
Controls
	T2211		S897L	1.11	0.18	96		39	12	106		0.21	0.07	129
BA31	T3265		FRT, S897L	1.08	0.32	121		39	11	114		0.20	0.06	101
Newly phenotyped recombinants
BA143	T3525	P744T	FRT, S897L	0.96	0.24	10	0.9	43	7	10	1.1	0.21	0.06	7	1.1
BA189	T3658	E756D	FRT, S897L	1.20	0.22	21	1.1	107	14	9	2.7	0.22	0.07	12	1.1
	T2483	M844T		1.59	0.52	16	1.4	96	22	16	2.5	0.28	0.10	10	1.3
	T2785	M844T	C592G (UL97)	2.75	0.89	19	2.5	79	18	18	2.0	0.25	0.04	9	1.2
BA187	T3652	M844V	FRT, S897L	2.50	0.54	11	2.3	84	27	12	2.2	0.32	0.08	22	1.6

^aMutation transferred into baseline strain or clone.

^bOther pol sequence changes from strain AD169 or UL97 change in case of T2785. FRT, FLP recombinase recognition sequence used for BAC mutagenesis.

^cMean drug concentration (μM) required to reduce SEAP growth by 50% at 6 to7 days postinfection. Values in bold indicate drug resistance (EC₅₀ > 1.9 times of control value).

^dStandard deviation of the EC₅₀ values.

^eN, number of assays (replicates performed over at least 4 independent assay setups).

^fRatio of EC₅₀ to that of matching baseline strain.